How next-gen mass spectrometry provides sensitivity & specificity over the current gold standard in clinical protein assays, ELISA.
How next-gen mass spectrometry provides sensitivity & specificity over the current gold standard in clinical protein assays, ELISA.
See how we deliver bespoke services for metabolomics, lipidomics, and proteomics data generation and analysis.
Dr. Jonathan Usuka appointed Chief Executive Officer as Founder Dr. Mohit Jain transitions to Chief Scientific Officer.
Using mass spectrometry to deliver quantitative measures for specific proteins in plasma, cells, and tissue.
The Foundation’s Impact Report highlights breakthroughs in our collaboration on the first diagnostic for persistent Lyme.
Sapient joins experts from Boehringer Ingelheim, ASU, The Institute of Cancer Research, London, & SciLifeLab to discuss.
From Oxford Global’s Multi-Omics Symposium, sharing examples of proteomics & metabolomics applied in drug discovery.
Biocom California spotlights how Sapient is making waves in drug development through dynamic biomarker discovery.
See how how the collaboration will enable accelerated delivery of multidimensional insights to inform drug development.
Explore our semi-targeted LC-MS/MS method optimized specifically for analysis and discovery of bioactive metabolites.
